Eating or Drinking Up to 1 Hour Before Bedtime May Impair Sleep Quality

September 14th 2021, 7:00pm


Eating or drinking less than 1 hour before bedtime was associated with increased risk of wake after sleep onset, a key symptom of chronic insomnia that significantly correlates with poor sleep quality.

Norwegian Study Shows CPAP Use Linked to Improving Insomnia in Patients With Sleep Apnea

September 11th 2021, 3:00pm


Adherence to continuous positive airway pressure (CPAP) resulted in a large decrease in insomnia and a significant reduction in prevalence of insomnia from baseline to follow-up in patients with obstructive sleep apnea.

How Daytime Light Exposure Affects Sleep, Mood-Related Outcomes

September 7th 2021, 7:45pm


Each additional hour spent outside during the day was associated with lower odds of later sleep-, mood-, and circadian-related adverse outcomes.

Emerging Trends in Sleep: Treating Central Disorders of Hypersomnolence, Breath Biomarkers in OSA, and More

August 27th 2021, 3:00pm


A roundup of the latest news in sleep research reported across MJH Life Sciences™.

Comorbid Insomnia Exacerbates Health Care Utilization, Cost Burden in Patients With Alzheimer Disease

August 24th 2021, 4:00pm


Patients with comorbid Alzheimer disease and insomnia were found to be more likely to report claims of higher cost health care services such as inpatient hospitalization and emergency care, along with significantly greater mean total annual health care costs than those without insomnia.

AHA Releases Scientific Statement on OSA, Cardiovascular Disease Link in Children and Adolescents

August 18th 2021, 9:00am


The scientific statement addresses current knowledge regarding the impact of obstructive sleep apnea on the cardiovascular health of children and adolescents, as well as best practices to evaluate symptoms.

Emerging Trends in Sleep: Pediatric Narcolepsy Scale, How Race Influences Classification of OSA Severity, and More

August 15th 2021, 6:00pm


A roundup of the latest news in sleep research reported across MJH Life Sciences™.

FDA Approves Jazz Pharmaceuticals’ Xywav for Idiopathic Hypersomnia

August 12th 2021, 9:00pm


Jazz Pharmaceuticals’ Xywav oral solution is the first treatment to be approved for adults with idiopathic hypersomnia.

Once-Nightly Sodium Oxybate Shown to Significantly Improve Symptoms of Narcolepsy

August 12th 2021, 5:30pm


Results of the phase 3 REST-ON study exhibited significant improvement in patients with narcolepsy treated with once-nightly sodium oxybate, FT218, versus placebo.

Survey Reveals Decrease in Symptoms of Central Hypersomnias During Pandemic Lockdowns

August 7th 2021, 12:00pm


Relaxed social and professional constraints brought on by pandemic-related lockdowns benefitted the sleep schedules of patients with central hypersomnias.